Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12521MR)

This product GTTS-WQ12521MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12521MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2122MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ15681MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ9796MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ10184MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ11035MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCLA-128
GTTS-WQ3502MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ11091MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ9994MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KD-247
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW